Issue Information

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2025)

Issue Information
Publié: (2025)

Issue Information
Publié: (2025)

Issue Information
Publié: (2025)

Issue Information
Publié: (2025)

Issue Information
Publié: (2026)

Issue Information
Publié: (2025)

Issue Information
Publié: (2026)

Issue Information
Publié: (2025)

Issue Information
Publié: (2026)

Issue Information
Publié: (2025)

Issue Information
Publié: (2025)

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes
par: Enrico Attardi, et autres
Publié: (2024)

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
par: Cristina A. Tentori, et autres
Publié: (2024)

Definitions matter: Multicenter investigation of incidence and outcome of poor graft function after hematopoietic cell transplantation
par: Konradin F. Müskens, et autres
Publié: (2024)

Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53‐deficient myeloma cells
par: Romane Durand, et autres
Publié: (2024)

Stage‐adapted treatment of HIV‐associated Hodgkin lymphoma: Long‐term results of a prospective, multicenter study
par: Marcus Hentrich, et autres
Publié: (2024)

30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
par: Enrique M. Ocio, et autres
Publié: (2024)

Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients
par: Cristina De Ramón, et autres
Publié: (2024)

Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?
par: Baptiste Le Calvez, et autres
Publié: (2024)

Prospective phase II study of allogeneic hematopoietic stem cell transplantation with targeted busulfan, fludarabine, and etoposide conditioning in pediatric acute lymphoblastic leukemia
par: Kyung Taek Hong, et autres
Publié: (2024)

Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia
par: Bela Patel, et autres
Publié: (2024)

News on sickle cell disease: Heme‐driven disordered erythropoiesis
par: Francesca Vinchi
Publié: (2024)

IDALLO study: A retrospective multicenter study of the SFGM‐TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1‐mutated AML after allogeneic hematopoietic cell transplantation
par: Adrien Caillet, et autres
Publié: (2024)

Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma
par: Wassilis S. C. Bruins, et autres
Publié: (2024)

Bone marrow niches for hematopoietic stem cells
par: Ana Luísa Pereira, et autres
Publié: (2024)

Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
par: Gian Matteo Rigolin, et autres
Publié: (2024)

An integrated classification of tumor suppressor IKZF1 inactivation and oncogenic activation in Philadelphia chromosome‐like acute lymphoblastic leukemia
par: Zicong Huang, et autres
Publié: (2024)

Annual Sickle Cell & Thalassaemia Conference (ASCAT) ‐ October 2023
Publié: (2024)

Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
par: Adrián Mosquera‐Orgueira, et autres
Publié: (2024)

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA
par: Christian M. Vonk, et autres
Publié: (2024)

Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma
par: Daniel Pölöske, et autres
Publié: (2024)

The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma
par: Anna de Daniel, et autres
Publié: (2024)